The University of Chicago Header Logo

Connection

Jeffrey Matthews to Piperazines

Back to Details
This is a "connection" page, showing publications Jeffrey Matthews has written about Piperazines.
Jeffrey Matthews
Connection Strength
0.038
Piperazines
  1. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 07 12; 39(7):989-998.e5.
    View in: PubMed
    Score: 0.038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.